ibrutinib
Ibrutinib is a drug used to treat Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, and other conditions. Ibrutinib is being actively studied in 153 studies and prior, has been studied in 66.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| Pharmacyclics LLC. | Ohio State University Comprehensive Cancer Center | Jennifer Woyach |
| National Cancer Institute (NCI) | Memorial Sloan Kettering Cancer Center | Brian Jonas |
| M.D. Anderson Cancer Center | M D Anderson Cancer Center | Kerry Rogers |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
O
Recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib Resistance
- Ibrutinib
- +2 more
- Columbus, OhioOhio State University Comprehensive Cancer Center
2021-10-29
Oct 29, 2021K
Withdrawn
- Chronic Lymphocytic Leukemia
- Loss of Chromosome 17p
- Ibrutinib
- Venetoclax
- (no location specified)
2021-10-29
Oct 29, 2021J
Active, not recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Mantle-Cell
- Ibrutinib
- Paris Cedex 13, France(unnamed)
2022-03-24
Mar 24, 2022S
Active, not recruiting
- Relapsed/Refractory Chronic Lymphocytic Leukemia
- +2 more
- Ibrutinib
- Venetoclax
- Aarau, Switzerland
- +10 more
2022-03-10
Mar 10, 2022N
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- VAY736
- ibrutinib
- La Jolla, California
- +4 more
2021-12-03
Dec 3, 2021C
Recruiting
- Glioblastoma
- Ibrutinib
- +2 more
- Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
2022-01-07
Jan 7, 2022T
Recruiting
- Ependymoma
- +3 more
- Ibrutinib
- +3 more
- Augusta, GeorgiaAugusta University, Georgia Cancer Center
2022-03-20
Mar 20, 2022C
Recruiting
- Waldenstrom Macroglobulinemia
- Carfilzomib + Ibrutinib
- Ibrutinib
- Salzburg, Austria
- +16 more
2022-03-11
Mar 11, 2022D
Active, not recruiting
- Waldenstrom Macroglobulinemia
- MYD88 Gene Mutation
- IBRUTINIB
- Venetoclax
- Boston, Massachusetts
- +1 more
2022-04-01
Apr 1, 2022D
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- +2 more
- Ibrutinib
- Copanlisib
- Boston, MassachusettsDana-Farber Cancer Institute
2021-09-08
Sep 8, 2021W
Recruiting
- Waldenstrom Macroglobulinemia
- +6 more
- Ibrutinib
- Daratumumab
- New York, New YorkWeill Cornell Medicine
2021-12-21
Dec 21, 2021J
Recruiting
- Chronic Lymphocytic Leukemia
- Daratumumab
- +3 more
- Columbus, OhioOhio State University Comprehensive Cancer Center
2022-02-24
Feb 24, 2022U
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer - 2021
Completed
- Metastatic Renal Cell Cancer
- Stage IV Renal Cell Cancer
- Ibrutinib
- Nivolumab
- Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
2022-02-08
Feb 8, 2022N
Recruiting
- Graft Vs Host Disease
- Rituximab
- Ibrutinib
- Atlanta, GeorgiaNorthside Hospital
2022-04-04
Apr 4, 2022N
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Ibrutinib
- Fludarabine
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-03-01
Mar 1, 2022U
Completed
- Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
- Ibrutinib
- Cologne, Germany1st Department of Medicine, Cologne University Hospital
2021-04-06
Apr 6, 2021P
Not yet recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Venetoclax
- +2 more
- (no location specified)
2022-04-02
Apr 2, 2022U
Active, not recruiting
- Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
- Refractory Transformed B-cell Non-Hodgkin Lymphoma
- Ibrutinib
- Laboratory Biomarker Analysis
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-01-20
Jan 20, 2022L
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Pirtobrutinib
- Ibrutinib
- (no location specified)
2022-02-15
Feb 15, 2022M
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Venetoclax
- Ibrutinib
- La Jolla, CaliforniaUC San Diego Moores Cancer Center
2021-05-06
May 6, 2021N
Recruiting
- Chronic GVHD
- Ibrutinib
- Bethesda, Maryland
- +1 more
2022-04-07
Apr 7, 2022M
Recruiting
- T-cell Lymphoma
- Relapsed and Refractory T-cell Lymphoma
- Ibrutinib
- New York, New York
- +1 more
2021-11-08
Nov 8, 2021D
Active, not recruiting
- Waldenstrom's Macroglobulinemia
- Ibrutinib
- Boston, Massachusetts
- +1 more
2021-12-15
Dec 15, 2021G
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib
- Placebo
- Cologne, GermanyGerman CLL Study Group
2021-12-16
Dec 16, 2021M
Recruiting
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
- +2 more
- Ibrutinib
- Houston, TexasUniversity of Texas MD Anderson Cancer Center
2021-10-29
Oct 29, 2021